Has Bryan Dibuono, MD received payments from drug or device companies?

Yes. Drug and device makers reported $988 in general payments to Bryan Dibuono, MD across 48 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bryan Dibuono, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bryan Dibuono, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bryan Dibuono, MD

Gastroenterology · Slidell, LANPI 1508057688

Payments from drug & device makers

$988in general payments, 2019–2025

Across 48 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$267
Sanofi$175
QOL Medical, LLC$133
Regeneron Healthcare Solutions, Inc.$111
Johnson & Johnson$70
Phathom Pharmaceuticals, Inc.$47
plus $185 from 8 others

What the payments were for

Food & beverage$988100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	9	$267
Sanofi	8	$175
QOL Medical, LLC	9	$133
Regeneron Healthcare Solutions, Inc.	4	$111
Johnson & Johnson(2 entities)	4	$70
Phathom Pharmaceuticals, Inc.	3	$47
Ironwood Pharmaceuticals, Inc	2	$37
Takeda Pharmaceuticals U.S.A., Inc.	2	$31
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$29
Ardelyx, Inc.	1	$25
Nestle Healthcare Nutrition Inc.	1	$17
Mallinckrodt Hospital Products Inc.	1	$17
Vertex	1	$15
Mallinckrodt Enterprises LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$106

How this compares

$988 in reported general payments places this provider in the 20th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$91,377

Medicare patients

379

Services billed

760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LinzessLinaclotide	79	$69,608
CreonLipase/Protease/Amylase	16	$26,345
Pantoprazole Sodium	532	$5,637
Fluticasone Propionate HfaFluticasone Propionate	12	$3,229
Sucralfate	36	$1,972
Esomeprazole Magnesium	58	$1,681
Omeprazole	77	$1,354
Clarithromycin	17	$327
Dicyclomine Hcl	15	$257
Amoxicillin	16	$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieLinzess, Creon	$267	$95,95395 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 254 gastroenterology providers in Louisiana.